SG11201909022PA - ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF - Google Patents
ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOFInfo
- Publication number
- SG11201909022PA SG11201909022PA SG11201909022PA SG11201909022PA SG 11201909022P A SG11201909022P A SG 11201909022PA SG 11201909022P A SG11201909022P A SG 11201909022PA SG 11201909022P A SG11201909022P A SG 11201909022PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- indianapolis
- n3pglu
- antibodies
- company
- Prior art date
Links
- 102000013455 Amyloid beta-Peptides Human genes 0.000 title abstract 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 abstract 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- 206010044688 Trisomy 21 Diseases 0.000 abstract 1
- 230000008021 deposition Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762487550P | 2017-04-20 | 2017-04-20 | |
| PCT/US2018/027718 WO2018194951A1 (fr) | 2017-04-20 | 2018-04-16 | Anticorps anti-peptides bêta-amyloïdes n3pglu et utilisations associées |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201909022PA true SG11201909022PA (en) | 2019-11-28 |
Family
ID=62111232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909022P SG11201909022PA (en) | 2017-04-20 | 2018-04-16 | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US10647759B2 (fr) |
| EP (1) | EP3612559A1 (fr) |
| JP (3) | JP6900500B2 (fr) |
| KR (2) | KR102567295B1 (fr) |
| CN (2) | CN110582511B (fr) |
| AR (1) | AR111208A1 (fr) |
| AU (2) | AU2018255221B2 (fr) |
| BR (1) | BR112019018810A2 (fr) |
| CA (1) | CA3058482C (fr) |
| CL (1) | CL2019002922A1 (fr) |
| CO (1) | CO2019011349A2 (fr) |
| CR (1) | CR20190445A (fr) |
| DO (1) | DOP2019000241A (fr) |
| EA (1) | EA201992163A1 (fr) |
| EC (1) | ECSP19075146A (fr) |
| IL (1) | IL269003A (fr) |
| JO (1) | JOP20190247A1 (fr) |
| MA (1) | MA50144A (fr) |
| MX (2) | MX2019012445A (fr) |
| NZ (1) | NZ758066A (fr) |
| PE (1) | PE20200011A1 (fr) |
| PH (1) | PH12019502361A1 (fr) |
| SA (1) | SA519410311B1 (fr) |
| SG (1) | SG11201909022PA (fr) |
| TW (2) | TWI705975B (fr) |
| UA (1) | UA126806C2 (fr) |
| WO (1) | WO2018194951A1 (fr) |
| ZA (1) | ZA202007868B (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201827467A (zh) | 2016-11-03 | 2018-08-01 | 比利時商健生藥品公司 | 焦穀胺酸類澱粉蛋白－β之抗體及其用途 |
| JOP20190247A1 (ar) * | 2017-04-20 | 2019-10-20 | Lilly Co Eli | أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها |
| SG11202110504XA (en) | 2019-03-26 | 2021-10-28 | Janssen Pharmaceutica Nv | ANTIBODIES TO PYROGLUTAMATE AMYLOID-ß AND USES THEREOF |
| WO2021151011A2 (fr) * | 2020-01-24 | 2021-07-29 | The Board Of Trustees Of Western Michigan University | Traitement de protéinopathies neurodégénératives à l'aide d'une molécule inhibitrice de l'apoptose fas (faim) ou d'un de ses fragments et/ou mimétiques |
| AU2021355521A1 (en) | 2020-10-02 | 2023-05-11 | Eli Lilly And Company | Methods for reducing host cell protein content in antibody purification processes and antibody compositions having reduced host cell protein content |
| WO2022150735A1 (fr) | 2021-01-11 | 2022-07-14 | Eli Lilly And Company | Anticorps anti-n3pglu bêta-amyloïde et leurs utilisations |
| TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
| TW202300518A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗N3pGlu類澱粉β抗體及其用途 |
| WO2022251048A1 (fr) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anticorps anti-amyloïde bêta et leurs utilisations |
| JP7306746B2 (ja) * | 2021-09-16 | 2023-07-11 | 株式会社ユニバーサルエンターテインメント | 遊技機 |
| JP7306745B2 (ja) * | 2021-09-16 | 2023-07-11 | 株式会社ユニバーサルエンターテインメント | 遊技機 |
| JP7268910B2 (ja) * | 2021-09-16 | 2023-05-08 | 株式会社ユニバーサルエンターテインメント | 遊技機 |
| AU2022371475A1 (en) | 2021-10-22 | 2024-05-09 | Eli Lilly And Company | O-glcnacase (oga) inhibitor combination therapy |
| CA3236547A1 (fr) | 2021-10-29 | 2023-05-04 | Marcio Chedid | Composes et methodes ciblant l'interleukine-34 |
| TW202336034A (zh) | 2021-10-29 | 2023-09-16 | 美商美國禮來大藥廠 | 靶向介白素-34之化合物及方法 |
| AU2022376930A1 (en) | 2021-10-29 | 2024-05-02 | Eli Lilly And Company | Compounds and methods targeting interleukin-34 |
| CA3236504A1 (fr) | 2021-10-29 | 2023-05-04 | Eli Lilly Company | Composes et procedes ciblant l'interleukine-34 |
| WO2023150483A1 (fr) | 2022-02-03 | 2023-08-10 | Eli Lilly And Company | Imagerie de tau régionale pour le diagnostic et le traitement de la maladie d'alzheimer |
| CN117327168A (zh) * | 2022-06-24 | 2024-01-02 | 厦门大学 | B2M-GluN1封闭肽、其药物组合物及用途 |
| WO2024107683A1 (fr) * | 2022-11-17 | 2024-05-23 | Eli Lilly And Company | Anticorps bêta-amyloïdes anti-n3pglu, doses et utilisations associées |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101670105B (zh) * | 2000-02-24 | 2014-08-06 | 华盛顿大学 | 螯合淀粉样蛋白β肽的人源化抗体 |
| US7122374B1 (en) | 2002-04-09 | 2006-10-17 | Takaomi Saido | Amyloid beta-protein 3(pE)-42 antibodies and uses thereof |
| JP2006513259A (ja) | 2002-07-24 | 2006-04-20 | イノジェネティックス・ナムローゼ・フェンノートシャップ | ベータ−アミロイド生成および／または凝集に関連した疾病の防止、処置および診断 |
| EP1666061A1 (fr) | 2003-09-09 | 2006-06-07 | Takeda Pharmaceutical Company Limited | Utilisation d'un anticorps |
| SG190665A1 (en) | 2004-07-30 | 2013-06-28 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and methods using same |
| UY29504A1 (es) * | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos. |
| CA2657681C (fr) | 2006-07-14 | 2019-03-19 | Ac Immune S.A. | Anticorps humanises contre la proteine beta-amyloide |
| CA2723995A1 (fr) | 2008-06-12 | 2009-12-17 | Affiris Ag | Composes destines au traitement de symptomes associes a la maladie de parkinson |
| JP2011527338A (ja) | 2008-07-09 | 2011-10-27 | ユニバーシティー オブ チューリッヒ | 神経新生を促進する方法 |
| CN102131519B (zh) | 2008-07-21 | 2016-01-13 | 前体生物药物股份公司 | 诊断抗体测定 |
| US8795664B2 (en) | 2010-06-04 | 2014-08-05 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Monoclonal antibodies targeting amyloid beta oligomers |
| PL3042917T3 (pl) * | 2010-08-12 | 2018-07-31 | Eli Lilly And Company | Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie |
| WO2012021475A2 (fr) | 2010-08-12 | 2012-02-16 | Eli Lilly And Company | ANTICORPS CONTRE LE PEPTIDE N3pGLU AMYLOÏDE BÊTA ET LEURS UTILISATIONS |
| WO2015175769A1 (fr) * | 2014-05-15 | 2015-11-19 | Biogen Ma Inc. | Procédés de détection d'oligomères bêta-amyloïdes dans des échantillons biologiques |
| TWI599358B (zh) | 2014-09-16 | 2017-09-21 | 美國禮來大藥廠 | 組合療法 |
| TWI703159B (zh) * | 2015-04-13 | 2020-09-01 | 美商輝瑞股份有限公司 | Bcma特異性治療性抗體及其用途 |
| JOP20170004B1 (ar) * | 2016-01-15 | 2022-09-15 | Lilly Co Eli | الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته |
| TWI798751B (zh) | 2016-07-01 | 2023-04-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| JOP20190247A1 (ar) * | 2017-04-20 | 2019-10-20 | Lilly Co Eli | أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها |
-
2017
- 2017-06-16 JO JOP/2019/0247A patent/JOP20190247A1/ar unknown
-
2018
- 2018-04-09 AR ARP180100882A patent/AR111208A1/es unknown
- 2018-04-09 TW TW107112023A patent/TWI705975B/zh active
- 2018-04-09 TW TW109140166A patent/TWI789644B/zh active
- 2018-04-16 PE PE2019002050A patent/PE20200011A1/es unknown
- 2018-04-16 KR KR1020227001314A patent/KR102567295B1/ko active IP Right Grant
- 2018-04-16 CN CN201880025982.6A patent/CN110582511B/zh active Active
- 2018-04-16 CR CR20190445A patent/CR20190445A/es unknown
- 2018-04-16 WO PCT/US2018/027718 patent/WO2018194951A1/fr unknown
- 2018-04-16 UA UAA201910202A patent/UA126806C2/uk unknown
- 2018-04-16 NZ NZ758066A patent/NZ758066A/en unknown
- 2018-04-16 KR KR1020197030416A patent/KR102352670B1/ko active IP Right Grant
- 2018-04-16 BR BR112019018810A patent/BR112019018810A2/pt unknown
- 2018-04-16 SG SG11201909022P patent/SG11201909022PA/en unknown
- 2018-04-16 US US15/953,716 patent/US10647759B2/en active Active
- 2018-04-16 MX MX2019012445A patent/MX2019012445A/es unknown
- 2018-04-16 CN CN202310757235.4A patent/CN117024583A/zh active Pending
- 2018-04-16 EP EP18722325.0A patent/EP3612559A1/fr active Pending
- 2018-04-16 AU AU2018255221A patent/AU2018255221B2/en active Active
- 2018-04-16 CA CA3058482A patent/CA3058482C/fr active Active
- 2018-04-16 JP JP2019551563A patent/JP6900500B2/ja active Active
- 2018-04-16 MA MA050144A patent/MA50144A/fr unknown
- 2018-04-16 EA EA201992163A patent/EA201992163A1/ru unknown
-
2019
- 2019-08-29 IL IL26900319A patent/IL269003A/en unknown
- 2019-09-20 DO DO2019000241A patent/DOP2019000241A/es unknown
- 2019-10-14 CL CL2019002922A patent/CL2019002922A1/es unknown
- 2019-10-15 CO CO2019011349A patent/CO2019011349A2/es unknown
- 2019-10-16 SA SA519410311A patent/SA519410311B1/ar unknown
- 2019-10-17 MX MX2022011817A patent/MX2022011817A/es unknown
- 2019-10-17 PH PH12019502361A patent/PH12019502361A1/en unknown
- 2019-10-18 EC ECSENADI201975146A patent/ECSP19075146A/es unknown
-
2020
- 2020-04-08 US US16/843,503 patent/US11078261B2/en active Active
- 2020-12-17 ZA ZA2020/07868A patent/ZA202007868B/en unknown
-
2021
- 2021-06-14 AU AU2021203927A patent/AU2021203927B2/en active Active
- 2021-06-16 JP JP2021099897A patent/JP7227312B2/ja active Active
- 2021-08-02 US US17/391,821 patent/US20210371509A1/en active Pending
-
2023
- 2023-02-09 JP JP2023018535A patent/JP2023058623A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201909022PA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201810371XA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201900844UA (en) | Amino pyrimidine ssao inhibitors | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201907032RA (en) | Amino pyrimidine compounds useful as ssao inhibitors | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201908540PA (en) | Stable antibody formulation | |
| SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201805420SA (en) | Antibodies and conjugates thereof | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201408261UA (en) | Syringe | |
| SG11201407655TA (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201901673SA (en) | Imidazole derivatives and their use in the treatment of autoimmune or inflammatory diseases or cancers | |
| SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch | |
| SG11201907208XA (en) | Radiolabeled anti-lag3 antibodies for immuno-pet imaging | |
| SG11201808882QA (en) | Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof |